307 related articles for article (PubMed ID: 25786447)
1. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
[TBL] [Abstract][Full Text] [Related]
3. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
Kunst H; Khan KS
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1374-81. PubMed ID: 20937175
[TBL] [Abstract][Full Text] [Related]
4. Treatment of latent tuberculosis infection: An update.
Lobue P; Menzies D
Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults.
Devrim I; Olukman O; Can D; Dizdarer C
Chest; 2010 Mar; 137(3):737-8. PubMed ID: 20202962
[No Abstract] [Full Text] [Related]
8. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
Duarte R; Carvalho A; Correia A
Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
[No Abstract] [Full Text] [Related]
9. Needed: new and better tools to combat latent tuberculosis infection.
Blumberg HM
Ann Intern Med; 2008 Nov; 149(10):761-3. PubMed ID: 19017594
[No Abstract] [Full Text] [Related]
10. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
White MC; Tulsky JP; Lee JR; Chen L; Goldenson J; Spetz J; Kawamura LM
J Correct Health Care; 2012 Apr; 18(2):131-42. PubMed ID: 22419641
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
Zenner D; Beer N; Harris RJ; Lipman MC; Stagg HR; van der Werf MJ
Ann Intern Med; 2017 Aug; 167(4):248-255. PubMed ID: 28761946
[TBL] [Abstract][Full Text] [Related]
12. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
Menzies D; Long R; Trajman A; Dion MJ; Yang J; Al Jahdali H; Memish Z; Khan K; Gardam M; Hoeppner V; Benedetti A; Schwartzman K
Ann Intern Med; 2008 Nov; 149(10):689-97. PubMed ID: 19017587
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
14. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
[TBL] [Abstract][Full Text] [Related]
15. Treatment of latent tuberculosis infection: a network meta-analysis.
Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
[TBL] [Abstract][Full Text] [Related]
16. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
Tersigni C; Venturini E; Cordola C; Piccini P; Bianchi L; Montagnani C; Sollai S; Chiappini E; de Martino M; Galli L
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):359-365. PubMed ID: 29465259
[TBL] [Abstract][Full Text] [Related]
17. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
Reichman LB; Lardizabal A; Hayden CH
Am J Respir Crit Care Med; 2004 Oct; 170(8):832-5. PubMed ID: 15297274
[No Abstract] [Full Text] [Related]
18. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis: which drug regimen and when.
Hall J; Elliott C
J Fam Pract; 2015 Jan; 64(1):27-33. PubMed ID: 25574509
[TBL] [Abstract][Full Text] [Related]
20. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
Fluegge KR
J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
